



wherein R may be H, alkenyl of 2-8 carbons, alkyl of 1-8 carbons, phenylalkyl of 1-4 carbons, phenyl or COR<sub>2</sub>, wherein R<sub>2</sub> may be H, alkyl of 1-8 carbons, alkenyl of 2-8 carbons, phenylalkyl wherein the alkyl has 1-4 carbons (including benzyl) or R<sub>2</sub> may be phenyl, and wherein any phenyl moiety may have up to three substituents chosen from among hydroxy, carboxy of 1-4 carbons, halo, alkoxy of 1-4 carbons, alkyl of 1-4 carbons, or alkenyl of 2-4 carbons and wherein any alkyl may be a straight chain, branched chain, or the alkyl may be wholly or partially cyclized, in a pharmaceutically acceptable carrier, said formulation being in the form of a capsule or tablet.

19. (Twice Amended) A composition of matter comprising an effective amount of 5-androstene-3 $\beta$ ,17 $\alpha$ - diol or an ester or ether of the formula:





Wherein R may be H, alkenyl of 2-8 carbons, alkyl of 1-8 carbons, phenylalkyl of 1-4 carbons, phenyl or COR<sub>2</sub>, wherein R<sub>2</sub> may be H, alkyl of 1-8 carbons, alkenyl of 2-8 carbons, phenylalkyl wherein the alkyl has 1-4 carbons (including benzyl) or R<sub>2</sub> may be phenyl, and wherein any phenyl moiety may have up to three substituents chosen from among hydroxy, carboxy of 1-4 carbons, halo, alkoxy of 1-4 carbons, alkyl of 1-4 carbons, or alkenyl of 2-4 carbons and wherein any alkyl may be a straight chain, branched chain, or the alkyl may be wholly or partially cyclized, in a pharmaceutically acceptable carrier, wherein said 5-androstene-3 $\beta$ ,17 $\alpha$ - diol or ester or ether thereof is part of a cyclodextrin inclusion complex.

---

**REMARKS**

Entry of the foregoing, reexamination and further and favorable reconsideration of the subject application in light of the following remarks, pursuant to and consistent with 37 C.F.R. § 1.112, are respectfully requested.

By the present amendment, claims 15 and 19 have been amended to recite that an effective amount of the compound is present in the composition. Support for this amendment to claims 15 and 19 may be found throughout the specification as filed. Specifically, see page 3, lines 25-27, of the specification as filed, wherein it recites that a sufficient dosage would provide a blood concentration of from 5 to 10,000 nM. No new matter has been added by the present amendment.